Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC02290, officially termed Long intergenic non-protein coding RNA 2290, is a human gene that produces a long intergenic non-protein coding RNA[1]. LINC02290 belongs to the **long intergenic non-coding RNA (lincRNA)** class, which are RNAs longer than 200 nucleotides that do not overlap with protein-coding regions[3]. This class of RNA is widely involved in regulating gene expression by modulating chromatin structure, controlling transcription, stabilizing RNA, and in some cases, acting through enhancer-like mechanisms[3][5]. While the general class of lincRNAs has important regulatory roles—sometimes impacting cell proliferation, apoptosis, and cancer—the specific molecular function, disease relevance, and therapeutic value of LINC02290 itself have not been established in available scientific or biomedical literature. There are no known approved drugs, clinical biomarkers, or safety issues directly linked to LINC02290 at this time[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2290 (LINC02290).